Reconsidering the usefulness of long-term high-dose buprenorphine

被引:0
|
作者
Jain, Lakshit [1 ]
Meeks, Thomas W. [2 ]
Blazes, Christopher K. [2 ]
机构
[1] Univ Connecticut, Dept Psychiat, Farmington, CT USA
[2] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA
来源
FRONTIERS IN PSYCHIATRY | 2024年 / 15卷
关键词
nitazenes; safety; opioid use disorder (OUD); fentanyl; buprenorphine (BN); high dose; high potency synthetic opioids; prescription opiates; NORBUPRENORPHINE; ABUSE; EXPOSURE; MISUSE;
D O I
10.3389/fpsyt.2024.1401676
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Buprenorphine has been successfully used for decades in the treatment of opioid use disorder, yet there are complexities to its use that warrant attention to maximize its utility. While the package insert of the combination product buprenorphine\naloxone continues to recommend a maximum dose of 16 mg daily for maintenance, the emergence of fentanyl and synthetic analogs in the current drug supply may be limiting the effectiveness of this standard dose. Many practitioners have embraced and appropriately implemented novel practices to mitigate the sequelae of our current crisis. It has become common clinical practice to stabilize patients with 24 - 32 mg of buprenorphine daily at treatment initiation. Many of these patients, however, are maintained on these high doses (>16 mg/d) indefinitely, even after prolonged stability. Although this may be a necessary strategy in the short term, there is little evidence to support its safety and efficacy, and these high doses may be exposing patients to more complications and side effects than standard doses. Commonly known side effects of buprenorphine that are likely dose-related include hyperhidrosis, sedation, decreased libido, constipation, and hypogonadism. There are also complications related to the active metabolite of buprenorphine (norbuprenorphine) which is a full agonist at the mu opioid receptor and does not have a ceiling on respiratory suppression. Such side effects can lead to medical morbidity as well as decreased medication adherence, and we, therefore, recommend that after a period of stabilization, practitioners consider a trial of decreasing the dose of buprenorphine toward standard dose recommendations. Some patients' path of recovery may never reach this stabilization phase (i.e., several months of adherence to medications, opioid abstinence, and other clinical indicators of stability). Side effects of buprenorphine may not have much salience when patients are struggling for survival and safety, but for those who are fortunate enough to advance in their recovery, the side effects become more problematic and can limit quality of life and adherence.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Switching From High-Dose, Long-Term Opioids to Buprenorphine: A Case Series
    Becker, William C.
    Frank, Joseph W.
    Edens, Ellen L.
    [J]. ANNALS OF INTERNAL MEDICINE, 2020, 173 (01) : 70 - U137
  • [2] HIGH-DOSE AND LONG-TERM USE OF ONDANSETRON
    VOHRA, S
    JURICIC, J
    [J]. ANNALS OF PHARMACOTHERAPY, 1992, 26 (01) : 128 - 129
  • [3] RENAL CALCIFICATIONS - COMPLICATION OF LONG-TERM HIGH-DOSE FUROSEMIDE
    HUFNAGLE, K
    PENN, D
    WILLIAMS, P
    [J]. JOURNAL OF PEDIATRICS, 1978, 93 (02): : 314 - 315
  • [4] Long-term high-dose cholecalciferol in patients with heavy proteinuria
    Singer, Richard F.
    [J]. CLINICAL KIDNEY JOURNAL, 2011, 4 (05) : 310 - 312
  • [5] INDUCTION OF PUBERTY - LONG-TERM TREATMENT WITH HIGH-DOSE LHRH
    BROOK, CGD
    DOMBEY, S
    [J]. CLINICAL ENDOCRINOLOGY, 1979, 11 (01) : 81 - 87
  • [6] Safety of long-term high-dose minocycline in the treatment of acne
    Goulden, V
    Glass, D
    Cunliffe, WJ
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1996, 134 (04) : 693 - 695
  • [7] Long-term surveillance of high-dose occupational dioxin exposure
    Pelclova, Daniela
    [J]. TOXICOLOGY LETTERS, 2012, 211 : S24 - S24
  • [8] Predictors of Long-Term and High-Dose Use of Zolpidem in Veterans
    Kim, Hyungjin Myra
    Gerlach, Lauren B.
    Van, Tony
    Yosef, Matheos
    Conroy, Deirdre A.
    Zivin, Kara
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2019, 80 (02)
  • [9] Reconsidering the Usefulness of Adding Naloxone to Buprenorphine
    Blazes, Christopher K.
    Morrow, Jonathan D.
    [J]. FRONTIERS IN PSYCHIATRY, 2020, 11
  • [10] High-dose chemotherapy - High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results
    Salerno, MG
    Ferrandina, G
    Greggi, S
    Pierelli, L
    Menichella, G
    Leone, G
    Scambia, G
    Mancuso, S
    [J]. BONE MARROW TRANSPLANTATION, 2001, 27 (10) : 1017 - 1025